Clinical Manifestation
Two studies have so far reported on SARS among children. In one study, persistent fever, cough, progressive chest radiograph changes and lymphopenia were noted in all 10 patients (Hon). Teenage patients presented with symptoms of malaise, myalgia, chill, and rigor similar to those seen in adults, whereas the younger children presented mainly with a cough and runny nose, and none had chills, rigor, or myalgia.
In the second study, fever was the presenting symptom in 19 of 21 children. Other prodromal symptoms reported included malaise, loss of appetite, chills, dizziness, and rhinorrhea. Headache, myalgia, diarrhea, sore throat, and skin rash were relatively uncommon (Chiu; Table 1). During the lower respiratory phase of the illness, approximately one half of the children had coughing, one third of which was productive. Dyspnea or tachypnea was uncommon (Chiu).
At presentation, all 21 children had normal hemoglobin values. The total white cell count was low in five children (23.8%). All neutrophil counts were normal. Twelve children (57.1%) had lymphopenia, and five (23.8%) had thrombocytopenia (Chiu). Subsequently, during the course of the disease, 19 children (90.5%) developed lymphopenia and ten of them (47.6%) had mild thrombocytopenia. All elevated activated partial thromboplastin time levels during the acute phase in six children (28.6%) subsequently returned to normal levels. D-dimer was abnormal in three children (14.3%). All children had normal renal function. Abnormal ALT levels were found in two children (9.5%) at admission. Mild biochemical hepatitis, defined as an elevation three times that of a normal ALT level with a normal bilirubin level, was observed in five children (23.8%). Fifteen children (71.4%) had a raised LDH level, and nine children (42.9%) had a raised CPK level (Chiu).
- April 8-10
- April 12
- June 6
- August 14
- September 8
- September 24
- References
- 30 Virology
- Discovery of the SARS Virus
- Initial Research
- Coronaviridae
- SARS Co-V
- Genome Sequence
- Antiviral Agents and Vaccines
- Antiviral Drugs
- Vaccines
- Outlook
- References
- Routes of Transmission
- Patient Factors in Transmission
- Asymptomatic Patients
- Symptomatic Patients
- The Unsuspected Patients
- High-Risk Activities
- Transmission during Quarantine
- Introduction
- Global Spread
- Hong Kong
- Other Countries
- Eradication
- Outlook
- Introduction
- International Coordination
- Management of SARS in the post-outbreak period
- National Measures
- Legislation
- Quarantine after Discharge
- Infection Control in Healthcare Settings
- General Measures
- Protective Measures
- Special Settings
- Intensive Care Units
- Intubating a SARS Patient
- Anesthesia
- Triage
- Internet Sources
- After the Outbreak
- Conclusion
- 108 Case Definition
- WHO Case Definition
- Suspect case
- Reclassification of cases
- CDC Case Definition
- 112 Diagnostic Tests
- Introduction
- Laboratory tests
- Virus isolation
- Antibody detection
- Interpretation
- Limitations
- Biosafety considerations
- Clinical Presentation and Diagnosis
- Clinical Presentation
- Diagnosis
- Clinical Course
- Histopathology
- Lung Biopsy
- Postmortem Findings
- Discharge and Follow-up
- Psychosocial Issues
- References
- 144 SARS Treatment
- Antibiotic therapy
- Antiviral therapy
- Ribavirin
- Alternative medicine
- Immunomodulatory therapy
- Other immunomodulators
- Assisted ventilation
- Invasive mechanical ventilation
- Clinical outcomes
- Appendix 1
- A standardized treatment protocol for adult SARS in Hong Kong
- Appendix 2
- A treatment regimen for SARS in Guangzhou, China
- References
- 168 Pediatric SARS
- Clinical Manifestation